Home » Business » Celltrion Healthcare launches’Remsima SC’ in France

Celltrion Healthcare launches’Remsima SC’ in France

[FETV=김창수 기자] Remsima SC (ingredient name: Infliximab), a subcutaneous injection biopharmaceutical for the treatment of autoimmune diseases, sold (directly sold) by Celltrion Healthcare, started to expand sales in Europe as the first prescription was made in France.

Celltrion Healthcare, after launching’Remsima SC’ in France earlier this month, hosted a’Remsima SC Launch Online Press Conference’ on the 11th as part of marketing activities.

At the event, Professor Laurent Peyrin-Birule, who is the chairman of the European Crohn’s & Colitis Organization (ECCO), belonging to Nancy General Hospital, France, Professor Bernard Kombe, a rheumatologist at Montpellier General Hospital, and Celltrion Healthcare, a French subsidiary. Dr. Salim Benquilipa attended and presented the clinical data of’Remsima SC’ and the meaning of the launch in France.

At the presentation, Professor Laurent Peyrin-Birule said, “With the release of’Remsima SC’, the dream of an infliximab subcutaneous injection for medical staff and patients has come true.” “We think very deeply about being able to provide’Sima SC’, and this innovation is the result of Celltrion Healthcare’s efforts to provide better treatment options for IBD disease.”

Participants at the conference also listened to the presentations of French KOL (Key Opinion Leader) doctors, expressing their expectation that’Remsima SC’ will establish itself as a safe and effective treatment plan for French patients.

The French autoimmune disease market targeted by’Remsima SC’ amounts to about 1.1 trillion won. Celltrion Healthcare recently won an order for Infliximab in a bid for UNIHA, the largest university hospital association in France, and decided to supply’Remsima IV’. This represents 30% of the French infliximab market and is expected to generate synergy with the sales of’Remsima SC’, as the company’s achievements through its direct drug sales infrastructure in France.

With the release of’Remsima SC’, Celltrion Healthcare is expected to create synergies with the strength of the dual formulation that allows customized treatment according to the patient’s condition along with the existing IV formulation, and tailored to the needs of patients and medical staff. It plans to strengthen marketing activities.

An official from Celltrion Healthcare said, “A positive atmosphere is spreading in France, including prescriptions for’Remsima SC’ from the first day of launch.” “Launched in Spain and Italy in the first quarter of this year, we will launch products in five major European countries. It is planned to be finished, and at the same time, we plan to expand the release to Belgium, Portugal, and Finland to concentrate our capabilities on selling’Remsima SC’.”

In addition, he added, “The adalimumab biosimilar’YUFLYMA’, which was approved for sale by the European Commission (EC) last week, has also begun preparations for the European launch of’Remsima IV’ in the autoimmune disease market. , “We will build a robust product portfolio with’Remsima SC’ to provide customized treatment options for patients.”

– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.